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Available online xxxxIncreased native myocardial T1 times in chronic kidney disease (CKD) may be due to diffuse interstitial myocar-
dial ﬁbrosis (DIF) or due to interstitial edema/inﬂammation. Concerns relating to nephrogenic systemic ﬁbrosis
with gadolinium-based contrast agents (GBCA) limit their use in end-stage kidney disease (ESKD) to measure
extracellular volume (ECV) and characterise myocardial ﬁbrosis. This study aimed to examine stability of
myocardial T1 and T2 times before, andwithin 2months after kidney transplantation; a time framewhenvolume
status normalises but myocardial remodelling is unlikely to have occurred, and to compare these with ECV using
GBCA after transplantation. Twenty-four patients with ESKD underwent serial cardiovascular magnetic
resonance imaging, including T1 and T2 mapping. GBCA was administered on follow-up provided eGFR was
N30 ml/min/1.73 m2. Eighteen age- and sex-matched controls were studied at one timepoint. ECV (ECV 28 ±
2% vs. 24± 2%, p= 0.001) and T2 times were higher in ESKD compared to controls. After transplantation, septal
T1 times increased (MOLLI 985ms±25 vs. 1002ms±30, p=0.014; ShMOLLI 974 ms ± 39 vs. 992 ms ± 33,
p = 0.113), LV volumes reduced (LVEDvol indexed 79 ± 24 vs. 63 ± 20 ml/m2, p = 0.005) but LV mass was
unchanged (LV mass index 89 g/m2 ± 38 to 83 g/m2 ± 23, p = 0.141). T2 times did not change after transplan-
tation. Both ECV andmyocardial T1 times are elevated in ESKD, supporting the theory that elevated T1 times are
due to DIF, although a contribution frommyocardial edema cannot be fully excluded. The lack of any fall in T1 or
T2 times after transplantation suggests that myocardial T1 times are a stable measure of DIF in CKD.




Multiparametric T1/T2 mapping1. Introduction
Cardiovascular (CV) disease is the leading cause of mortality in
patients with chronic kidney disease (CKD). Most of the excess CV
mortality in patients with end-stage kidney disease (ESKD) arises
from heart failure, arrhythmia and sudden cardiac death rather than
atherothrombotic events such as myocardial infarction; these events
are thought to be attributable to uremic cardiomyopathy (UC) [1].
Histological and imaging studies have shown that this speciﬁc heart
muscle disease is characterised by left ventricular hypertrophy (LVH)ltrials.gov. Unique identiﬁer:
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onal Journal of Cardiology, httand interstitialﬁbrosis causing left ventricular (LV) systolic and diastolic
dysfunction, and is almost universal in the hemodialysis population.
Studies using cardiacmagnetic resonance imaging have shown changes
consistentwith coarse replacementﬁbrosis and diffuse interstitialﬁbro-
sis (DIF) in both early and advanced CKD [2–5].More recently, the use of
gadolinium-based contrast agents (GBCA) in ESKD has been restricted
following case reports of nephrogenic systemic ﬁbrosis. As a result,
myocardial characterization has been investigated using native T1
mapping. This technique measures relaxivity that is characteristic of
the tissue studied but does not distinguish between the intracellular
and extracellular compartments. Emerging data show that native myo-
cardial T1 times are prolonged in hemodialysis patients and in early
stage CKD. These ﬁndings have been interpreted as due to DIF however
this assumption is complicated by the fact that native T1 times can also
be prolonged by free water in the myocardium (interstitial and extra-
cellular edema, inﬂammation) [4,6,7]. This is especially pertinent in
ESKD, when patients are often chronically volume overloaded. Studying
renal transplant recipients shortly after kidney transplantation providesarly effects of kidney transplantation on the heart - A cardiacmagnetic
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renal function. This allows measurement of ECV in ESKD at a time
when uremic cardiomyopathy is unlikely to have changed. We
hypothesised that both ECV and native T1 times would be elevated in
subjects with ESKD studied shortly after transplantation. If so, this
would provide evidence that the elevated T1 times previously reported
in these subjects are likely to be due to DIF rather than to increased
myocardial water content.
2. Methods
2.1. Study design and participants
Patients who were due to undergo living-donor kidney transplantation were re-
cruited as part of an ongoing BHF-funded study (NCT03176862). All patients were in
sinus rhythm. Subjects were excluded if they had a history or symptoms of CV disease
or diabetes mellitus. CV disease was deﬁned as any history of ischemic heart disease,
peripheral vascular disease, stroke, heart failure, or LV ejection fraction b45% or more
than mild valvular disease. All patients underwent exercise stress echocardiography or
99m technetium tetrofosmin single photon electron computed tomography (SPECT) to
exclude silent myocardial ischemia. Demographic and medical comorbidity data and
bloods were collected on both visits. Estimated glomerular ﬁltration rate (eGFR) was
assessed using the Modiﬁcation of Diet in Renal Disease equation. Eighteen age- and
sex-matched healthy controls were also recruited. Healthy subjects had normal kidney
function (deﬁned as an eGFR N60 ml/min/1.73 m2 and the absence of structural or histo-
logical renal abnormality), no known chronic disease, andwere not on regularmedication.
Subjects were recruited through advertisement at the University of Birmingham or
University Hospitals Birmingham. Control subjects had blood tests and a CMR scanat base-
line. Stress echocardiography or SPECT were not performed in these individuals.
2.2. Cardiac magnetic resonance imaging
Baseline CMR (1.5 TMagnetomAvanto, SiemensHealthcare, Germany)was performed
before the transplant, and within 2 months following kidney transplantation. Cine images
for LV and right ventricular (RV) volumes, function, and LV mass were acquired using
breath-hold steady state free precession sequences as previously described [8]. T1mapping
was performed at basal and mid short axis (SAX) level in diastole using a Shortened Mod-
iﬁed Look-Locker Inversion recovery sequence (ShMOLLI, Oxford) 5(1)1(1)1 heart beats
and ECG-gated Modiﬁed Look-Locker Inversion recovery (MOLLI) sequence with a 3(3)3
(3)5 heart beats sampling protocol. ShMOLLI T1 mapswere generated with variable inver-
sion preparation time. Typical acquisition parameterswere: TE= 1.05ms, ﬂip angle= 35°,
matrix size 192× 144, slice thickness 7mm, voxel size=1.9 × 1.9 × 7mm, FoV=360mm.
Typical acquisition parameters for the MOLLI sequence were: pixel bandwidth 977 Hz/
pixel; TE = 1.1 ms; ﬂip angle = 35°; matrix size = 144 × 256, slice thickness 7 mm,
voxel size 2.5 × 2 × 7 mm. Motion correction and a non-linear least-square curve ﬁtting
were performed with the set of images acquired at different MOLLI inversion times to gen-
erate a parametric pixel-wise colour T1 map to quantitatively measure the longitudinal
myocardial relaxation time. For T2 maps, 3 single shot images were acquired at different
T2-preparation times (0ms, 24ms, and 55ms, respectively) in the basal andmid SAX slices
with the following typical acquisition parameters: ECG triggered, TE = 1.12 ms, ﬂip angle
= 70°, voxel size: 2.2 × 1.8 × 6.0 mm, slice thickness 6 mm. Motion correction and ﬁtting
were performed to estimate coefﬁcients of the decay function, whichwere then used to es-
timate the T2 times. The T2 sequence was acquired later in our study and therefore only
performed in 15 patients at baseline, but in all patients at follow up. LGE imaging was ac-
quired using a standard inversion recovery sequence 7 to 10 min after administration of
GBCA bolus (0.15 mmol/kg of Gadovist). Post-contrast MOLLI T1 images were acquired
≥15 min after GBCA administration at the same levels as pre-contrast. ShMOLLI T1 images
were not acquired post-contrast. GBCA was administered on the follow up CMR scan pro-
vided eGFR had risen to N30 ml/min/1.73 m2 and the patient consented.
2.3. Phantom studies
Phantom studies were also undertaken to assess the stability of our T1 sequences. The
T1 Mapping and ECV Standardisation (T1MES) phantom was scanned every 2 weeks for
6 months as part of the T1MES multicentre study, according to the user manual instruc-
tions distributed to centres, and as previously described. Analysis was done ofﬂine as pre-
viously described [9].
2.4. Analysis of CMR scans
Ofﬂine analysis was performed using CVi 42® software (version 5.3.4, Circle Vascular
Imaging, Canada) by an experienced reader blinded to clinical information. Manual
planimetry of the short axis epicardial and endocardial borders in end-diastole and end-
systole was performed using standardised methods for determination of LV ejection frac-
tion, volumes and mass [10]. For analysis of parametric maps, endocardial and epicardial
borders were manually drawn in the basal and mid short axis slices and a 20% offset
was used to avoid blood pool contamination. Anterior and inferior septal borderswere de-
ﬁnedwith semi-automated segmentalization of the LV in accordancewith theAHAmodel.Please cite this article as: M.K. Hayer, A. Radhakrishnan, A.M. Price, et al., E
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artefact were excluded. A region of interest was drawn in the blood pool, taking care to
avoid papillary muscle. ECV was calculated with the pre and post contrast T1 maps
using a previously validated formula [4]. An inter-observer and intra-observer analysis
of the MOLLI sequence only was also done by two experienced individuals to ensure
there was no systematic bias in the T1 analysis technique. For analysis of global longitudi-
nal strain smoothed endocardial and epicardial borders were drawn in the end-diastolic
frame of all three long axis images and automatically propagated throughout the cardiac
cycle using the feature tracking software. For global circumferential strain, smoothed en-
docardial and epicardial borders were drawn in the end-diastolic frame of SAX cines,
and the anterior and inferior RV insertion points were deﬁned on each SAX slice. The
basal slice was taken as the ﬁrst SAX slice without the LV outﬂow tract.
2.5. Statistical analysis
Data normality was assessed using the Shapiro-Wilk test. Continuous variables are
expressed as mean ± SD (normal distribution) or median (interquartile range [IQR];
non-normal distribution). Paired group comparisons for continuous data were made
using the paired samples t-test or the Wilcoxon Signed Rank test for parametric and
non-parametric data respectively. Unpaired group comparisons for continuous data
were made using the unpaired t-test or the Mann Whitney U test. Paired categorical
data were compared using the McNemar test. Statistical tests were 2-tailed, and a p
value b0.05 was considered to indicate statistical signiﬁcance. A per protocol analysis
was performed for the 21 patients with paired data. An intention-to-follow-up analysis
was also done assuming variables did not change between baseline and follow up.
3. Results
3.1. Subject characteristics
Twenty-four patients were studied before kidney transplantation
(median 8 days, IQR 4 to 11 days). The median time between baseline
and repeat CMR scan was 7 weeks (IQR 6 to 9 weeks). Three patients
were lost to follow up: 1 relocated to another geographical area and
the other two had post-operative complications and withdrew consent
for further CMR within 2 months. Table 1 describes the demographic
details and subject characteristics for the CKD and control populations.
Eleven patients were on hemodialysis prior to transplantation, three
were on peritoneal dialysis, and ten underwent pre-emptive kidney
transplantation. The median dialysis vintage was 15 months [IQR 8 to
24 months]. Hemodialysis patients were scanned 10 to 24 h after dialy-
sis. At follow up, 14 patients consented to receive GBCA. The reason for
refusal in the remaining subjects was anxiety about protecting their
new kidney and avoiding unnecessary contrast agents. Two patients
developed new onset diabetes after transplantation. The number of pa-
tients on antihypertensive medication reduced from 20 to 18, and the
type of antihypertensive agents also changed (Table 1). Only one
patient was on immunosuppression (prednisolone) before kidney
transplantation. Following surgery, subjects were on a typical immuno-
suppressive regime of tacrolimus, mycophenolate mofetil and prednis-
olone. There was no difference in LV volumes at baseline between the
CKD cohort and healthy controls, but LV mass was higher in ESKD.
After transplantation, LV mass was unchanged, LV volumes were re-
duced, and there was a small increase in LV ejection fraction (Table 2).
3.2. Myocardial function and tissue character
4% of shMOLLI segments and 4%MOLLI segmentswere excluded due
to artefact, most commonly in inferior and lateral segments. At baseline,
native global and septal T1 times and T2 times were higher in the CKD
cohort than in healthy controls (Table 2). ECV was also higher in the
CKD cohort than in healthy controls. On per protocol analysis there
was a small but statistically signiﬁcant increase in septal T1 times after
kidney transplantation (Fig. 1(a) MOLLI; (b) ShMOLLI; Fig. 2). Global
T1 times were unchanged (Table 2). Similar directional changes were
seen regardless of the T1 sequence was used – T1 times increased in
14 subjects using both MOLLI and ShMOLLI. T2 times did not change
after transplantation. Blood pool T1 times decreased following kidney
transplantation, hemoglobin and hematocrit increased and heart rate
was unchanged. Of the 14 patients who were given GBCA on followarly effects of kidney transplantation on the heart - A cardiacmagnetic
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Table 2
CMR data for CKD patients at baseline and follow up with controls.
CKD (n = 21) Controls
(n = 18)
Baseline Follow up
LVEDvol indexed (ml/m2) (n = 21) 79 ± 24 63 ± 20⁎ 65 ± 13†
LVESvol indexed (ml/m2) (n = 21) 26 ± 16 20 ± 15 19 ± 6
LVEF (%) (n = 21) 68 ± 9 73 ± 9⁎ 70 ± 8
LV mass indexed (g/m2) (n = 21) 89 ± 38 83 ± 23 55 ± 11†
Septal T1 MOLLI (ms) (n = 18) 985 ± 25 1002 ± 30⁎ 962 ± 22†
Global T1 MOLLI (ms) (n = 18) 981 ± 29 983 ± 25⁎ 946 ± 30†
Blood pool T1 MOLLI (ms) (n = 18) 1593 ± 74 1520 ± 96⁎ 1462 ± 67†
Septal T1 ShMOLLI (ms) (n = 18) 974 ± 39 992 ± 33 916 ± 20†
Global T1 ShMOLLI (ms) (n = 18) 963 ± 45 960 ± 33⁎ 907 ± 23†
Blood pool T1 ShMOLLI (ms) (n = 18) 1586 ± 108 1570 ± 94 1497 ± 51†
Septal T2 (ms) (n = 15) 55.5 ± 4.0 54.6 ± 2.1 50 ± 2†
Global T2 (ms) (n = 15) 58.1 ± 7.3 59.1 ± 4.3 50 ± 2†
Blood pool T2 (ms) (n = 15) 201 ± 26 199 ± 38 190 ± 32
Septal ECV (%) (n = 14) n/a 28 ± 2 24 ± 2§
Global ECV (%) (n = 14) n/a 27 ± 2 24 ± 2§
Septal ICV (%) (n = 14) n/a 72 ± 2 76 ± 2§
Global ICV (%) (n = 14) n/a 73 ± 2 76 ± 2§
2D GLS (%) (n = 21) 15.6 ± 3.0 16.3 ± 2.5 19.0 ± 2.9†
2D GCS (%) (n = 21) 16.6 ± 3.2 17.2 ± 2.8 20.8 ± 3.8†
n/a, not applicable; LVEDvol, left ventricular end-diastolic volume; LVESvol, left ventricu-
lar end systolic volume; LVEF, left ventricular ejection fraction; ECV, extracellular volume
fraction; ICV, intracellular volume fraction; GLS, global longitudinal strain; GCS, global cir-
cumferential strain.
These data are from a per-protocol analysis, excluding the 3 patients at baseline who did
not go on to have a follow up scan.
⁎ Indicates p value b0.05 between paired data at baseline and transplant follow up.
† Indicates p values b0.05 between unpaired data comparing the transplant cohort at
baseline to healthy controls.
§ Indicates p values b0.05 between unpaired data comparing the transplant cohort at
follow up to healthy controls.
Table 1








Age 46 ± 13 n/a 49 ± 17
Male n (%) 17 (71) n/a 11 (61)
Dialysis vintage (months) 13 (8–33) n/a n/a
Weight (kg) 80.5 ± 13.9 80.2 ± 14.2 76.7 ± 7.7
Body surface area (kg/m2) 1.96 ± 0.21 1.96 ± 0.21 1.91 ± 0.14
Heat rate (beats/min) 73 ± 13 75 ± 14 75 ± 11
Systolic BP (mmHg) 133 ± 23 135 ± 18 125 ± 14







eGFR (ml/min/1.73 m2) – 47 (36–61)⁎ 83 (74–87)†
Hemoglobin (g/L) 124 ± 17 133 ± 15⁎ 140 ± 17†
Hematocrit 0.37 ± 0.05 0.40 ± 0.04⁎ 0.43 ± 0.29†
Ferritin (μg/L) 257 ± 162 186 ± 156 n/a
Cholesterol (mg/dL) 187 ± 036 195 ± 46 n/a
Primary glomerulonephritis
n (%)
7 (29) n/a n/a
Vasculitis n (%) 1 (4) n/a n/a
Polycystic kidney disease
n (%)
7 (29) n/a n/a
Hypertension n (%) 2 (8) n/a n/a
Other n (%) 7 (29) n/a n/a
Medications
CCB 10 14 n/a





n/a, not applicable; eGFR, estimated glomerular ﬁltration rate; CCB, calcium channel
blocker; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor
blocker.
⁎ Indicates p value b0.05 between paired data at baseline and transplant follow up
(n = 21).
† Indicates p values b0.05 between unpaired data comparing the transplant cohort at
baseline to healthy controls.
3M.K. Hayer et al. / International Journal of Cardiology xxx (xxxx) xxxup scans, 1 patient had LGE in amid-wall distribution and 3 patients had
right ventricular insertion point LGE, including one of the patients with
new onset diabetes. There were no signiﬁcant differences in LV vol-
umes,mass, ejection fraction,myocardial T1/T2 times or ECV in patients
with LGE compared to thosewithout. The subjectwithmidwall LGE had
extensive contrast uptake (LGE 34 g, 15 g/m2, 22% total), with elevated
T1 in the regionwith contrast uptake (Supplementary Fig. 1). Therewas
no systemic bias detected on Bland Altman Analysis of T1 between
readers, with an inter-reader difference of −1 ± 7 ms (−13 to 11),
and an intra-reader difference of−1 ± 6 ms (−12 to 10).
3.3. Phantom data
25 ShMOLLI and MOLLI phantom datasets were collected over the
study period (Supplementary Fig. 2). The scanner room temperature
was stable throughout the test period at 20.96 ± 0.98 °C. Unadjusted
for temperature, ShMOLLI and MOLLI T1 times across the 9 tubes were
stable with coefﬁcients of variation ranging between 0.511% to 1.585%
and 0.436% to 0.872% respectively. Stability of both sequences improved
further with temperature correction (0.500% to 1.495% and 0.436% to
0.868% respectively).
4. Discussion
This is the ﬁrst study in ESKD to comprehensively examine myocar-
dial structure and tissue character, including T2mapping and ECVmea-
surement, early after kidney transplantation. Patients with ESKDPlease cite this article as: M.K. Hayer, A. Radhakrishnan, A.M. Price, et al., E
resonance multi-parametric study, International Journal of Cardiology, httexhibited higher global and septal T1 and T2 times thanhealthy controls
and there was a small increase in T1 time after kidney transplantation.
At 8 weeks after transplantation, ECV measured using GBCA was ele-
vated in patients with ESKD. These ﬁndings support the hypothesis
that the elevated myocardial T1 times in ESKD are due to DIF. The
small elevation in T2 times in patients with ESKD compared to controls
means that it is not possible to exclude a contribution from myocardial
oedema to the increased T1 times. However it is important to note that
ECV is not particularly affected by T2 times sincemostmyocardialwater
is in the intracellular or intravascular spaces and not in the interstitial
space [11]. Although not performed here, a longitudinal measurement
of T2 times looking for late normalisation might clarify the importance
of myocardial edema in this population.
The ECV levels observed in patients with ESKD are consistent with
previously published myocardial histology data for patients with ESKD
that demonstrated DIF in uremic cardiomyopathy [12]. The number of
patients in our study who had LGE was too small to determinewhether
high T1 in ESKD alone could be used as a surrogatemarker for coarse re-
placement ﬁbrosis, although in the single case with mid-wall enhance-
ment, elevated T1 was detected that mapped to the area. Both global
and septal T1 times, were elevated in the CKD cohort compared to
healthy controls, which are consistent with other data from hemodialy-
sis patients [5,7]. Native myocardial T1 times increased very slightly
early after kidney transplantation indicating a change in myocardial tis-
sue composition. Given the trend to decreasing LVmass observed in this
study despite rising T1 times, it is possible that myocardial cellular re-
gression occurred. This would have increased the ratio of ECV to ICV,
thereby increasing myocardial T1 times, but could also be a reﬂection
of increasedwater content asmeasured by T2mapping. The absolute in-
crease in T1 times early after kidney transplantation was small, and the
clinical signiﬁcance of this change is unknown.
Previous studies of LV structure and function after kidney transplan-
tation are conﬂicting with echo studies showing improvement in LV
mass and ejection fraction [13–15] but CMR studies showing noarly effects of kidney transplantation on the heart - A cardiacmagnetic
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Fig. 1. (a). Comparison ofmyocardial T1 times between baseline and follow up usingMOLLI. The rectangle in each box andwhisker plot represents the interquartile range. The line inside
each box represents themedian value, and the lines at either end of thewhiskers represent themaximumandminimumvalues. (b). Comparison ofmyocardial T1 times between baseline
and follow up using ShMOLLI. The rectangle in each box and whisker plot represents the interquartile range. The line inside each box represents the median value, and the lines at either
end of the whiskers represent the maximum and minimum values.
4 M.K. Hayer et al. / International Journal of Cardiology xxx (xxxx) xxxsigniﬁcant change in LV mass, volume or function at one year after
transplantation [16]. Our data showed a reduction in LV end-diastolic
volume and an accompanying improvement in ejection fraction at
2 months following kidney transplantation but no change in LV
mass.
Left ventricular hypertrophywashighly prevalent in our CKDcohort,
mirroring the situation in the general ESKD population where it occurs
due to a combination of haemodynamic factors (arterial stiffness, in-
creased preload, activation of the renin angiotensin aldosterone system)
and circulating factors (hyperuricaemia, elevated levels of parathyroid
hormone and ﬁbroblast growth factor-23) [2,17,18]. It is unlikely that
LVH contributed signiﬁcantly to the changes in T1 times or ECV seen
here. We have previously shown that hypertensive patients with LVH
but no renal impairment have lower T1 times than patients with early
stage CKD [4]. Additionally, physiological LVH as a result of exercise
training is not associated with increased T1 times [19]. These data sug-
gest that raised LVMI alone cannot account for the increased T1 times
seen in ESKD.Please cite this article as: M.K. Hayer, A. Radhakrishnan, A.M. Price, et al., E
resonance multi-parametric study, International Journal of Cardiology, httThe results of this study are consistent with the results of previ-
ously published studies using T1 mapping in CKD. Two studies have
shown that native myocardial T1 times are elevated in hemodialysis
patients compared to healthy controls, although these were
performed at 3 T [5,7]. A longitudinal follow-up study of patients
showed no change in T1 time despite a reduction in LV mass and im-
provement of myocardial deformation after initiating dialysis [20].
Our earlier work has shown that ECV is also higher in patients with
early stage CKD compared to healthy and hypertensive controls [4].
Although ECV is the preferred non-invasive biomarker to measure
DIF, the necessity for GBCA precluded its measurement in our pre-
transplant population.
5. Limitations
There are several limitations to acknowledge. Patients with ESKD in
this study may not be representative of the general kidney transplant
population as they were highly selected, relatively young, and all werearly effects of kidney transplantation on the heart - A cardiacmagnetic
ps://doi.org/10.1016/j.ijcard.2019.06.007
Fig. 2. A typical example of T1 maps before and after kidney transplantation. Panel a is an example of a basal MOLLI map acquired in a patient before kidney transplantation. Panel b is a
basal MOLLI map acquired from the same patient after kidney transplantation. The colour scale at the bottom shows what T1 times the different colours represent. Normal myocardium
appears green, with red representing elevated T1 times. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
5M.K. Hayer et al. / International Journal of Cardiology xxx (xxxx) xxxrecipients of living kidney donation. These data cannot be extrapolated
to ESKDwith diabetes, previous cardiovascular events and coronary ar-
tery disease. While our study enables conclusions to be drawn about
‘pure’myocardial disease in ESKD, it is likely that a typical group of dial-
ysis patients will have a higher prevalence of both sub-endocardial and
mid wall LGE and of valvular disease. Moreover, our control population
was small and did not include patients with increased LVMI. It is now
recommended that for small-magnitude biological changes, as is likely
the case with diffuse myocardial ﬁbrosis in ESKD, high precision is re-
quired for native T1 and T2 mapping and that control populations
should be larger [21].
6. Conclusion
In conclusion ECV is elevated in kidney transplant recipients com-
pared to controls, supporting the suggestion that high myocardial T1
times in ESKD are indicative of DIF. The contribution of myocardial
edema toward the raised T1 times and ECV cannot be excluded since
T2 times were also mildly elevated.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2019.06.007.
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